Growth Metrics

Solid Biosciences (SLDB) Cash from Investing Activities (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Cash from Investing Activities for 8 consecutive years, with $38.6 million as the latest value for Q4 2024.

  • Quarterly Cash from Investing Activities fell 14.86% to $38.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$16.1 million through Dec 2024, down 266.02% year-over-year, with the annual reading at -$58.5 million for FY2025, 263.38% down from the prior year.
  • Cash from Investing Activities hit $38.6 million in Q4 2024 for Solid Biosciences, up from -$11.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2022 to a low of -$72.5 million in Q3 2021.
  • Historically, Cash from Investing Activities has averaged -$1.6 million across 5 years, with a median of -$47500.0 in 2020.
  • Biggest five-year swings in Cash from Investing Activities: crashed 90537.5% in 2021 and later surged 107937.14% in 2022.
  • Year by year, Cash from Investing Activities stood at -$60000.0 in 2020, then skyrocketed by 50393.33% to $30.2 million in 2021, then soared by 119.05% to $66.1 million in 2022, then crashed by 31.47% to $45.3 million in 2023, then decreased by 14.86% to $38.6 million in 2024.
  • Business Quant data shows Cash from Investing Activities for SLDB at $38.6 million in Q4 2024, -$11.0 million in Q3 2024, and -$5.2 million in Q2 2024.